Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
Study sponsor: Denali Therapeutics Inc. · DNLI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2032-07Estimated
Enrollment · participants30Estimated
Source updated2026-11-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.